Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Thyroid Neoplasms 2Lung Neoplasms 2Thoracic Neoplasms 1Solid Tumors 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Neoplasms, Nerve Tissue 1Neoplasms, Germ Cell and Embryonal 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasms 1Lung Diseases 1Head and Neck Neoplasms 1Carcinoma, Bronchogenic 1Carcinoma 1Bronchial Diseases 1Advanced Thyroid Cancer Patients Who Received Target Therapy 1Adenocarcinoma 1

Interventions

Bevacizumab 3contrast agent BR1 2pralsetinib 1pembrolizumab 1Pemetrexed 1Paclitaxel 1Microbubbles 1Gemcitabine 1Cisplatin 1Carboplatin 1Biopsy 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Nerve Tissue × pralsetinib × 1 year × Clear all
NCT04222972 2026-03-05

AcceleRET-Lung

Hoffmann-La Roche

Phase 3 Terminated
223 enrolled 18 charts
Head & NeckThoracic

Adenocarcinoma, Bronchial Diseases, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡